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In a recent issue of Cell, Leonard et al. (2011) describe the structure of PKCbII, an AGC kinase, revealing an
unanticipated intramolecular autoinhibitory interaction between its C-terminal tail and the diacylglycerol and
phorbol ester binding site of its C1b domain.The three-dimensional structure of an
intact protein kinase C (PKC), an arche-
typal lipid membrane effector, has long
been anticipated. Following determina-
tion of the kinase domain structures for
several AGC family Ser-Thr kinases
(named after prominent members of the
families PKA, PKG, and PKC), key ques-
tions have focused on how the kinase
domain is regulated by other domains in
these tightly controlled modular proteins.
In the January 7 issue of Cell, Leonard
et al. (2011) describe an important step
toward this goal, with a 4 A˚ resolution
structure of PKCbII that contains almost
80% of the intact protein–lacking only
one of the regulatory domains. The new
structure, supported by biochemical and
small-angle X-ray scattering studies,
adds an important new twist to our under-
standing of the multistep regulation of
PKC.
PKC isozymes are widely implicated in
human physiology and disease, and their
involvement in cancer progression is well
established. PKCs are described as clas-
sical (cPKCa, bI, bII, and g), novel (nPKCd,
3, h, and q), or atypical (aPKCz and l/i)
based on their biochemical requirementsfor activation. Only cPKCs respond to
calcium, whereas both cPKCs and nPKCs
are sensitive to phorbol esters and the
lipid second messenger diacylglycerol
(DAG). Activation of PKCs is well known
to proceed through multiple steps, the
first of which involves transphosphoryla-
tion (required for maturation to an activat-
able state) and autophosphorylation.
Even once ‘‘primed’’ by phosphorylation,
PKC isoforms remain ‘‘autoinhibited’’ by
intramolecular interactions between the
N-terminal pseudosubstrate region and
the active site of the C-terminal kinase
domain (Figure 1A). Relieving this autoin-
hibition also involves multiple steps. In
cPKCs, the C2 domain first binds Ca2+
and phospholipids, targeting the enzyme
to the membrane. Once membrane-asso-
ciated, binding of the C1 domains to DAG
is thought to reverse autoinhibition by the
pseudosubstrate region, leading to full
activation of the enzyme (Newton, 2009).
Now, the work from Hurley’s group
yields two major new findings. First, the
structure reveals an additional step in
the allosteric activation of PKCbII. The
kinase domain appears to be maintained
in an inactive state by unexpected intra-molecular autoinhibitory interactions
between the regulatory C1b domain and
an ‘‘NFD motif’’ in the C-terminal tail.
Second, the work argues that the two
C1 domains in PKCbII (C1a and C1b)
play substantially different roles, as pre-
dicted from several biochemical and
pharmacological studies (Colon-Gonza-
lez and Kazanietz, 2006) (see below).
As with all AGC kinases, the C-terminal
tail of PKCbII (residues 621-673) is an
important cis-acting regulatory module,
wrapping around the N-lobe of the kinase
domain (Figure 1B) to stabilize its active
conformation (Pearce et al., 2010). The
hydrophobic motif in the C-tail (residues
656-661) helps position the key aC helix
in the active structure, and the flexible
‘‘turn motif’’ (residues 624-650) contrib-
utes to the ATP binding site (Grodsky
et al., 2006). In PKCbII, phosphorylation
of these regulatory elements promotes
their ability to stabilize the active kinase.
Just as these C-tail interactions are
crucial for stabilizing the active kinase,
they also provide vulnerability that seems
to be exploited in PKCbII regulation. The
structure reported by Leonard et al.
(2011) reveals an intriguing intramolecular
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Figure 1. PKCbII Autoinhibition
(A) Domain composition of PKCbII. PS designates the pseudosubstrate region. The C-terminal tail is
colored red.
(B) Structure of kinase domain and C1b domain regions of PKCbII (from PDB ID 3PFQ). Kinase domain is
gray, C-tail is red, and C1b domain is cyan. F629 in the NFD motif is contained within a helix that limits its
access to the ATP binding site. The NFD helix and adjacent sequences project into the C1b DAG binding
site.
(C) Cartoon representation of PKCbII autoinhibition. Without C1b domain interaction, the NFD helix is
‘‘unwound,’’ and F629 can contribute to the ATP binding site. The intramolecular interaction with the
C1b domain stabilizes helix formation in the NFD motif, rotating F629 out of the ATP binding site, leading
to inhibition of the kinase.
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Previewsinteraction in which the C1b domain
of PKCbII docks onto a binding site
comprising residues 619-633 from the
regulatory C-tail plus conserved elements
in the kinase domain N-lobe. Moreover, it
is the DAG binding site of the C1b domain
that mediates this intramolecular contact.
Although intramolecular interactions
between the C1 domains and the rest of
PKCbII might have been expected, theirconsequence for the conformation of the
kinase domain was not. The region of
the C-tail that interacts with the C1b
domain is one that alternatively plays an
important role in stabilizing the active
site of the kinase domain, and has been
termed the ‘‘active-site tether’’ (Kannan
et al., 2007). In protein kinase A (PKA),
the side chain of a conserved phenylala-
nine (F327) in this region projects intoStructure 19, February 9, 2011the ATP-binding pocket and contacts
the bound nucleotide. In the PKCbII struc-
ture, the corresponding phenylalanine
(F629) instead contacts the C1b domain
and is prevented from participating in
ATP binding (Figure 1B). This key phenyl-
alanine lies in what Hurley and coworkers
call the ‘‘NFD motif.’’ The NFD motif is in
a region previously noted to be flexible in
PKCbII, and forms an a helix both in the
new PKCbII structure and in a structure
of the isolated inhibitor-bound PKCbII
kinase domain (Grodsky et al., 2006). By
contrast, this helix is not seen in an ATP-
bound active PKC kinase domain struc-
ture (Takimura et al., 2010), where the
NFD motif phenylalanine is freed to pro-
ject into the ATP-binding site (Figure 1C).
These structural details suggest an
attractive model. In the absence of DAG,
PKCbII is subject to at least two modes
of autoinhibition. One involves the pseu-
dosubstrate region. The second arises
because the DAG-binding site of the
C1b domain associates with the NFD
motif in the regulatory C-tail, and
‘‘clamps’’ it in a position that is suboptimal
for kinase activity (Figure 1C). In doing so,
an a helix is formed in the NFD region,
which appears to be characteristic of
the inactive state. Only when the C1b
domain is engaged by DAG (or phorbol
esters) is this clamp released (and the
NFD helix unfolded), allowing the kinase
to adopt its fully active configuration.
Other autoinhibitory sites may also need
to be released, such as those involving
isozyme-specific motifs required for intra-
cellular compartmentalization (Stebbins
and Mochly-Rosen, 2001).The C1 Domain: More than
a Lipid-Binding Motif
DAG or phorbol ester binding to C1
domains confers a high-affinity interaction
between PKC and the membrane.
Tandem C1 domains are found in cPKCs,
nPKCs, and other kinases (protein kinase
D isozymes and DAG kinases). Other
signaling proteins have only one C1
domain, including MRCK (myotonic
dystrophy kinase-related Cdc42 binding
kinase), Munc-13 scaffolding proteins,
and small G protein regulators such
as RasGRPs (guanine nucleotide ex-
changers) or the a- and b-chimaerins
(Rac GTPase activating proteins, or Rac-
GAPs).ª2011 Elsevier Ltd All rights reserved 145
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PreviewsAsmentionedabove, amajor suggestion
of the Hurley paper is that the C1a andC1b
domains in PKCbII have distinct roles.
Indeed, the functional nonequivalence of
C1a andC1b becameevident in early anal-
yses of membrane translocation of C1
domain mutants and later from biochem-
ical studies (Colon-Gonzalez and Kaza-
nietz, 2006). Despite significant sequence
homology, individual C1 domains also
differ in their ability to bind ligands and
penetrate membranes (Colon-Gonzalez
and Kazanietz, 2006). According to
the model postulated by Hurley and
coworkers, the C1a domain of PKCbII is
exposed and is the first to bind DAG in
the membrane after initial priming of PKC
by calcium. This step may provide the
energy fordisruptingautoinhibitory interac-
tions between the N-terminal pseudosub-
strate region and the kinase domain. Full
kinase activation then occurs only after
the C1b clamp is released from the NFD
motif, coincident with its association with
DAG.
Despite the obvious differences
between PKCs and proteins that contain
a single C1 domain, there are similarities
between the mechanisms of regulation
of PKCbII and b2-chimaerin, for example.
In both cases, the ‘‘closed’’ conformation
is stabilized by C1 domain association
with other domains in the same protein,
with which DAG/phorbol ester and
phospholipid binding must compete.
Like the C1b domain in the Hurley PKCbII
structure, the C1 domain in b2-chimaerin
is buried, contacting the catalytic
(Rac-GAP) domain and other regions.
Disrupting the intramolecular C1 domain146 Structure 19, February 9, 2011 ª2011 Elsinteractions by mutagenesis renders
b2-chimaerin more sensitive to phorbol
12-myristate 13-acetate (PMA)-induced
translocation to membranes and confers
elevated Rac-GAP activity (Canagarajah
et al., 2004). Leonard et al. (2011) see
a similar effect when they disrupt the
crystallographically observed clamp in
PKCbII. Interestingly, the chimaerins re-
quire a higher concentration of PMA for
translocation than PKCs do, possibly
reflecting a more extensive C1 domain
burial. However, in response to physio-
logical stimuli such as EGF, which gener-
ates DAG through activation of phospho-
lipase C, full translocation of chimaerins
is observed despite the lower affinity of
C1 domains for DAG than for PMA
(Colon-Gonzalez et al., 2008). DAG
binding to the C1 domain is required,
but not sufficient, for chimaerin transloca-
tion, suggesting that other factors con-
tribute to disruption of the intramolecular
autoinhibitory interactions. One possi-
bility is that association of other proteins
with the chimaerin N-terminal region
weakens intramolecular C1 domain inter-
actions. Interaction of PKCs with other
proteins appears crucial for dictating the
distinctive intracellular localization of
each isoform, and thus their differential
access to substrates. The C1 domains
may play a role in this. Indeed, both C1a
and C1b domains have been shown to
engage in protein-protein interactions,
one key example being the association
of p23/Tmp21 with the C1b domain of
nPKCs, anchoring them in the perinuclear
region (Colon-Gonzalez and Kazanietz,
2006).evier Ltd All rights reservedIt remains to be seen whether other
members of the PKC family follow the
same activation scheme as suggested
for PKCbII, but it is quite possible that
other PKCs and AGC kinases take advan-
tage of the flexibility of the NFD motif with
similar autoinhibitory clamps. Additional
regulatory mechanisms involving specific
protein interactions or posttranslational
modification may also exert their effects
through the NFD motif.REFERENCES
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